Tarsus Pharmaceuticals (TARS) Stock Price, News & Analysis

Company Overview

Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for diseases and conditions affecting the eye. The company concentrates on areas of significant unmet need in ophthalmology and aims to address conditions that can affect ocular health, comfort and vision.

Tarsus’ primary product is XDEMVY (lotilaner ophthalmic solution) 0.25%, an eye drop approved by the U.S. Food and Drug Administration in 2023 for the treatment of Demodex blepharitis. The condition is associated with an infestation of Demodex mites and can cause eyelid inflammation, irritation and other ocular symptoms. XDEMVY is the first FDA-approved treatment specifically indicated for Demodex blepharitis.

Founded in 2016 and headquartered in Irvine, California, Tarsus markets XDEMVY in the United States and continues to develop additional ophthalmic therapies. The company is led by President and Chief Executive Officer Bobak R. Azam, M.D., who has experience in the biotechnology and pharmaceutical industries.

Key Stats

• Today's Range: $70.55 to $74.94
• 50-Day Range: $64.79 to $90.78
• 52-Week Range: $53.89 to $91.53
• Volume: 1.40 million shs
• Average Volume: 861,168 shs
• Market Capitalization: $3.50 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $100.86
• Consensus Rating: Moderate Buy

Tarsus Pharmaceuticals Stock Analysis - MarketRank™

Tarsus Pharmaceuticals scored higher than 73% of companies evaluated by MarketBeat, and ranked 247th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Tarsus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 7 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Tarsus Pharmaceuticals has a consensus price target of $100.86, representing about 42.1% upside from its current price of $70.99.

Amount of Analyst Coverage

Tarsus Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Tarsus Pharmaceuticals are expected to grow in the coming year, from ($4.25) to $0.60 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tarsus Pharmaceuticals is -65.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tarsus Pharmaceuticals is -65.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tarsus Pharmaceuticals has a P/B Ratio of 8.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.31% of the float of Tarsus Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Tarsus Pharmaceuticals has a short interest ratio ("days to cover") of 8.29.

Change versus previous month

Short interest in Tarsus Pharmaceuticals has recently decreased by 0.93%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tarsus Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Tarsus Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.89

News Sentiment

Tarsus Pharmaceuticals has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Tarsus Pharmaceuticals this week, compared to 5 articles on an average week.

Search Interest

1 people have searched for TARS on MarketBeat in the last 30 days.

MarketBeat Follows

5 people have added Tarsus Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Tarsus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,004,227.00 in company stock.

Percentage Held by Insiders

9.64% of the stock of Tarsus Pharmaceuticals is held by insiders.

Percentage Held by Institutions

90.01% of the stock of Tarsus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/15/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:TARS
• CIK: 1819790
• Web: www.tarsusrx.com
• Phone: 949-409-9820
• Fax: N/A
• Employees: 370
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Tarsus Pharmaceuticals: $100.86
• High Price Target: $116.00
• Low Price Target: $88.00
• Potential Upside/Downside: +42.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$66.42 million
• Net Margins: -7.67%
• Pretax Margin: -6.49%
• Return on Equity: -13.53%
• Return on Assets: -8.12%

Debt

• Debt-to-Equity Ratio: 0.21
• Current Ratio: 3.20
• Quick Ratio: 3.17

Sales & Book Value

• Annual Sales: $451.36 million
• Price / Sales: 7.75
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.09 per share
• Price / Book: 8.78

Miscellaneous

• Outstanding Shares: 49,300,000
• Free Float: 39,653,000
• Market Cap: $3.50 billion
• Optionable: Optionable
• Beta: 0.44